Physician profile
Nicole M Bossenbroek
NPI 1619909611
$5,919.41
in general payments reported to CMS, 2019-2025
28 companies · $2,362 in 2025
The $2,362 reported for 2025 was more than what 89% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $218 · 2021: $158 · 2022: $75.44 · 2023: $73.34 · 2024: $2,320 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,732 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.09 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $829.83 | 2019-2025 | |
| Abbvie INC. | $803.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $430.15 | 2019-2025 | Libtayo, Dupixent |
| Amgen INC. | $371.37 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $367.30 | 2019-2025 | |
| Ucb, INC. | $360.74 | 2019-2025 | Bimzelx |
| Celgene Corporation | $327.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $264.45 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $222.42 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $214.82 | 2019-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $190.41 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $175.11 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $165.32 | 2021-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.08 | 2023-2024 | Spevigo, Cyltezo |
| Leo Pharma INC. | $116.47 | 2019-2025 | Adbry, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $113.52 | 2019-2024 | Siliq |
| Lilly USA, LLC | $110.82 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $101.66 | 2019-2025 | |
| Kyowa Kirin, INC. | $96.32 | 2024-2025 | Poteligeo |
| Organogenesis INC. | $85.32 | 2024 | |
| Organon LLC | $83.88 | 2024-2025 | Vtama |
| Genentech USA, INC. | $74.29 | 2024-2025 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $73.60 | 2024 | Sotyktu |
| Fresenius Kabi USA, LLC | $68.06 | 2024 | Idacio |
| Verrica Pharmaceuticals INC. | $52.56 | 2024 | Ycanth |
| Integra Lifesciences Corporation | $48.00 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Strata Skin Sciences, INC. | $27.21 | 2025 | Xtrac |
| Botanix Sb INC | $16.42 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bossenbroek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.